WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. (Q48882411)

16 February 2018

title

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. (English)

1 reference

16 February 2018

1 reference

1 reference

Maurizio Miglino

1

1 reference

16 February 2018

Nicoletta Colombo

2

1 reference

16 February 2018

Gianmatteo Pica

3

1 reference

16 February 2018

Raffaella Grasso

4

1 reference

16 February 2018

Marino Clavio

5

1 reference

16 February 2018

Micaela Bergamaschi

6

1 reference

16 February 2018

Filippo Ballerini

7

1 reference

16 February 2018

Anna Ghiso

8

1 reference

16 February 2018

Chiara Ghiggi

9

1 reference

16 February 2018

Laura Mitscheunig

10

1 reference

16 February 2018

Germana Beltrami

11

1 reference

16 February 2018

Antonia Cagnetta

12

1 reference

16 February 2018

Luana Vignolo

13

1 reference

16 February 2018

Maria Vita Lucchetti

14

1 reference

16 February 2018

Sara Aquino

15

1 reference

16 February 2018

Ivana Pierri

16

1 reference

16 February 2018

Mario Sessarego

17

1 reference

16 February 2018

Angelo Michele Carella

18

1 reference

16 February 2018

Marco Gobbi

19

1 reference

16 February 2018

publication date

1 October 2011

1 reference

16 February 2018

published in

Leukemia & Lymphoma

1 reference

16 February 2018

volume

52

1 reference

16 February 2018

issue

10

1 reference

16 February 2018

page(s)

1961-1969

1 reference

16 February 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Wilms tumor gene expression in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Clinical implications of molecular genetic aberrations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Independent prognostic factors for AML outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

AML in older patients: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

WT1 monitoring in core binding factor AML: comparison with specific chimeric products

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

The many facets of the Wilms' tumour gene, WT1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.585673

10.3109/10428194.2011.585673

21 January 2018

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018